Currently, there isn't a specific test to diagnose Parkinson's disease. A diagnosis is made by a doctor trained in nervous system conditions, known as a neurologist. A diagnosis of Parkinson's is based on your medical history, a review of your symptoms, and a neurological and physical exam.
A member of your health care team may suggest a specific single-photon emission computerized tomography (SPECT) scan called a dopamine transporter (DAT) scan. Although this can help support the suspicion that you have Parkinson's disease, it is your symptoms and results of a neurological exam that ultimately determine the correct diagnosis. Most people do not require a DAT scan.
Your care team may order lab tests, such as blood tests, to rule out other conditions that may be causing your symptoms.
Imaging tests — such as an MRI, ultrasound of the brain and PET scans — also may be used to help rule out other disorders. Imaging tests aren't particularly helpful for diagnosing Parkinson's disease.
In addition to examining you, a member of your health care team may give you carbidopa-levodopa (Rytary, Sinemet, others), a Parkinson's disease medicine. You must be given a sufficient dose to show the benefit, as getting low doses for a day or two isn't reliable. Significant improvement with this medicine will often confirm your diagnosis of Parkinson's disease.
Sometimes it takes time to diagnose Parkinson's disease. Health care professionals may recommend regular follow-up appointments with neurologists trained in movement disorders to evaluate your condition and symptoms over time and diagnose Parkinson's disease.
However, a new test may be on the horizon. Researchers are studying a Parkinson's test that can detect the disease before symptoms begin. The test is called an alpha-synuclein seed amplification assay. In a 2023 study, researchers tested the spinal fluid of more than 1,000 people to look for clumps of the protein alpha-synuclein. Alpha-synuclein is found in Lewy bodies. It forms clumps that the body can't break down. The clumps spread and damage brain cells.
Alpha-synuclein clumps are a hallmark sign of Parkinson's disease. The test accurately identified people with Parkinson's disease 87.7% of the time. The test also was highly sensitive for detecting people at risk of Parkinson's disease.
This study of the alpha-synuclein seed amplification assay was the largest so far. Some researchers say the study may be a game changer for Parkinson's disease diagnosis, research and treatment trials. But larger studies are needed. There's hope among researchers that in the future, the test could be done using blood samples rather than spinal fluid.